STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRIX
  4. [Form 4] Nurix Therapeutics, Inc. Insider Trading Activity

Nurix Therapeutics (NRIX) CLO sells 16,589 shares after option exercise

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised employee stock options for 5,787 shares of common stock at an exercise price of $8.72 per share and, on the same date, sold 16,589 common shares at a weighted average price of $23.0489 (within a $22.67–$23.30 range). Following the option exercise, 122,824 stock options tied to common stock remain outstanding, expiring in 2034. These transactions were effected under a previously adopted Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Ring Christine
Role Chief Legal Officer
Sold 16,589 shs ($382K)
Approx. gross sale proceeds $382K
Approx. exercise cost $50K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F1, F3 5,787 $0.00 $0.00
Exercise Common Stock F1 5,787 $8.72 $50K
Sale Common Stock F1, F2 16,589 $23.0489 $382K
Holdings After Transaction: Employee Stock Option (right to buy) — 122,824 shares (Direct); Common Stock — 9,110 shares (Direct)
Footnotes (3)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $22.67 and the highest price at which shares were sold was $23.30. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
  3. F3. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Shares sold 16,589 shares Common Stock sold on 2026-08-03 at weighted average price
Weighted average sale price $23.0489 per share Average price for Common Stock sales on 2026-08-03
Sale price range $22.67–$23.30 per share Lowest and highest prices in the reported share sales
Options exercised 5,787 shares Employee stock options exercised into Common Stock on 2026-08-03
Option exercise price $8.72 per share Exercise price of the employee stock option
Options remaining 122,824 shares Stock options remaining after exercise, expiring 2034-02-12
Rule 10b5-1 trading plan financial
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at"
Employee Stock Option financial
"security_title: Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
vests as to 1/36 of the total shares financial
"The stock option vests as to 1/36 of the total shares monthly"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider stock sale did Nurix Therapeutics (NRIX) report for Christine Ring?
Christine Ring sold 16,589 shares of Nurix Therapeutics common stock. The sale on August 3, 2026, was executed at a $23.0489 weighted average price per share, with prices ranging between $22.67 and $23.30, under a Rule 10b5-1 trading plan.

Did the NRIX insider transaction involve an option exercise by Christine Ring?
Yes. Christine Ring exercised 5,787 employee stock options, acquiring the same number of Nurix Therapeutics common shares. The options had an exercise price of $8.72 per share, and this exercise was part of the same Rule 10b5-1 trading plan as the reported stock sale.

At what prices were Nurix Therapeutics (NRIX) shares sold in Christine Ring’s transaction?
The shares were sold at a $23.0489 weighted average price per share. According to the disclosure, the lowest sale price was $22.67 and the highest was $23.30, with full price-by-price details available upon request from the company or regulators.

How many Nurix Therapeutics (NRIX) stock options does Christine Ring hold after this transaction?
After the reported option exercise, 122,824 stock options tied to Nurix Therapeutics common stock remain outstanding for Christine Ring. These options are scheduled to expire on February 12, 2034 and vest in monthly installments, subject to continued service.

Was Christine Ring’s NRIX stock sale under a Rule 10b5-1 trading plan?
Yes. The transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, meaning the timing of the 16,589-share sale and related 5,787-share option exercise was set in advance rather than chosen discretionarily.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ring Christine
(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026M(1)5,787A$8.7225,699D
Common Stock08/03/2026S(1)16,589D$23.0489(2)9,110D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$8.7208/03/2026M(1)5,787 (3)02/12/2034Common Stock5,787$0122,824D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. Represents the weighted average sale price. The lowest price at which shares were sold was $22.67 and the highest price at which shares were sold was $23.30. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR